Home / Recalls / Novo Nordisk Inc / D-0956-2016

D-0956-2016 Class II Terminated

Recalled by Novo Nordisk Inc — Princeton, NJ

Recall Details

Product Type
Drugs
Report Date
June 15, 2016
Initiation Date
April 27, 2016
Termination Date
May 2, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
723 pens

Product Description

Norditropin FlexPro Somatropin (rDNA origin) injection, 30 mg/3 mL Prefilled Pen, Rx only, Novo Nordisk Inc., Plainsboro, NJ --- NDC 0169-7703-21

Reason for Recall

Defective Delivery System; may have a low frequency assembly fault which may result in pens block during the so-called "air shot" step

Distribution Pattern

Nationwide

Code Information

Lot Number FC70222

Other recalls by Novo Nordisk Inc

  • D-0244-2026 Class II — Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Man (December 19, 2025)
  • D-0245-2026 Class II — Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manuf (December 19, 2025)
  • D-0621-2021 Class I — TRESIBA FlexTouch (insulin degludec injection) 200 units/mL (U-200), 3 mL Prefil (March 22, 2021)
  • D-0611-2021 Class I — Fiasp FlexTouch (insulin aspart injection) 100 units/mL (U-100), 3 mL Prefilled (March 22, 2021)
  • D-0614-2021 Class I — Levemir FlexTouch (insulin detemir) injection, 100 units/mL (U-100), 3 mL Prefil (March 22, 2021)
  • D-0613-2021 Class I — Fiasp (insulin aspart injection), 100 units/mL (U-100), One 10 mL multi-dose via (March 22, 2021)
  • D-0615-2021 Class I — NovoLog FlexPen (insulin aspart) Injection, 100 units/mL, 3 mL Prefilled Insulin (March 22, 2021)
  • D-0612-2021 Class I — Fiasp PenFill (insulin aspart injection) 100 units/mL (U-100), 3 mL cartridge, 5 (March 22, 2021)
  • D-0617-2021 Class II — OZEMPIC (semaglutide) injection, 2 mg/1.5 mL (1.34 mg/mL) Prefilled pen, 1 pen, (March 22, 2021)
  • D-0618-2021 Class II — Saxenda (liraglutide) Injection, 18 mg/3 mL (6 mg/mL), 1 x 3 mL Prefilled Pen, S (March 22, 2021)